Publications by authors named "Sandra Lockmer"

Claim this Profile
R
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia.
Magdalena Kättström, Bertil Uggla, Camilla Virta, Merit Melin, Nina Ekström, Sandra Lockmer

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting

Cancer Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment.
Wendy B C Stevens, G Tjitske Los-de Vries, Carole Langois-Jacques, Andrew J Clear, Phylicia Stathi, Sandra Lockmer

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden.
Caroline E Weibull, Tove Wästerlid, Björn Engelbrekt Wahlin, Per-Ola Andersson, Sara Ekberg, Sandra Lockmer

Hemasphere· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma - a comparison with normative data.
Cecilie E Kiserud, Sandra Lockmer, Idun Baerug, Alv A Dahl, Eva Kimby

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
Sara Alonso-Álvarez, Martina Manni, Silvia Montoto, Clémentine Sarkozy, Franck Morschhauser, Sandra Lockmer

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.
Sandra Lockmer, Katarina Uttervall, Muhammad Kashif, Carina Svärd, Katarina Malmsten

Am J Hematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
Eva Kimby, Sandra Lockmer, Harald Holte, Hans Hagberg, Björn E Wahlin

Br J Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
Henna-Riikka Junlén, Sandra Lockmer, Eva Kimby, Björn Engelbrekt Wahlin

Ann Hematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
Sandra Lockmer, Weicheng Ren, Marianne Brodtkorb, Bjørn Østenstad, Björn E Wahlin

Br J Haematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
Chloé B Steen, Ellen Leich, June H Myklebust, Sandra Lockmer, Jillian F Wise

Haematologica· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M. Sorigue et al.
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, Harald Holte, Ann-Sofie Johansson

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli, Vittoria Tarantino, Martina Manni, Sandra Lockmer

Lancet Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis